In vitro and in vivo platelet targeting by cyclic RGD-modified liposomes

Journal of Biomedical Materials Research - Part A

Volumn 93, Issue 3, 2010, Pages 1004-1015

  Srinivasan, Rekha ^a   Marchant, Roger E ^a   Gupta, Anirban Sen ^a  

^a Case Western Reserve University   (United States)

Author keywords

Cyclic RGD; Drug delivery; Platelets; Targeting

Indexed keywords

ACTIVATED PLATELETS; CAROTID ARTERY; CYCLIC RGD; EX-VIVO; IMAGING PROBE; IN-VITRO; IN-VITRO TESTS; IN-VIVO TESTS; INTEGRINS; LIGAND BINDING; NANO-GOLD; PHASE-CONTRAST MICROSCOPY; PLATELET ADHESION; RESTENOSIS; RGD PEPTIDE; SEM; SITE SELECTIVE; SURFACE-MODIFIED; TARGETED NANOPARTICLE; VASCULAR DISEASE;

BLOOD SUBSTITUTES; DRUG DELIVERY; EXCITONS; FLUORESCENCE; FLUORESCENCE MICROSCOPY; LIGANDS; LIPOSOMES; NANOPARTICLES; PEPTIDES; PHOSPHOLIPIDS; PLATELETS; PROBES; VISUALIZATION;

SCANNING ELECTRON MICROSCOPY;

ARGINYLGLYCYLASPARTIC ACID; GOLD NANOPARTICLE; LIPID; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAROTID ARTERY OBSTRUCTION; CATHETER; CONTROLLED STUDY; EUTHANASIA; EX VIVO STUDY; FLUORESCENCE MICROSCOPY; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LIPOPHILICITY; NONHUMAN; PHASE CONTRAST MICROSCOPY; RAT; RESTENOSIS; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; THROMBOCYTE ACTIVATION;

ANIMALS; BLOOD PLATELETS; CAROTID ARTERIES; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; HUMANS; LIPOSOMES; MICROSCOPY, FLUORESCENCE; NANOSTRUCTURES; PEPTIDES, CYCLIC; RATS;

EID: 77950649513     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32549     Document Type: Article

References (26)

1. Michelson AD. Platelets. New York: Academic Press; 2002.
2. Munker R, Hiller E, Glass J, Paquette R. Modern Hematology. Biology and Clinical Management. Totowa, NJ: Humana; 2007.
3. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378-3384.
4. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002;8:1227-1234.
5. Frenette PS, Denis CV, Weiss L, Jurk K, Subbarao S, Kehrel B, Hartwig JH, Vestweber D, Wagner DD. P-selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med 2000;191:1413-1422. (Pubitemid 30227127)
6. 3 integrin and GPIbα. J Exp Med 1998;187:329-339.
7. Verheul HMW, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MFBG, Pinedo HM. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 2000;96:4216-4221.
8. Lusis AJ. Atherosclerosis. Nature 2000;407:233-241.
9. von Hundelshausen P, Weber KSC, Huo Y, Proudfoot AEI, Nelson PJ, Ley K, Weber C. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001;103:1772-1777. (Pubitemid 32291415)
10. Plow EF, D'Souza SE, Ginsberg MH. Ligand binding to GPIIb-IIIa: A status report. Semin Thromb Hemost 1992;18:324-332.
11. Plow EF, Pierschbacher M, Ruoslahti E, Marguerie G, Ginsberg MH. Arginyl-glycyl-aspartic acid sequences and fibrinogen binding to platelets. Blood 1987;70:110-115. (Pubitemid 17111249)
12. 3 antagonists. J Med Chem 1994;37:1-8.
13. Coutré S, Leung L. Novel antithrombotic therapeutics targeted against platelet glycoprotein IIb/IIIa. Annu Rev Med 1995;46:257-265.
14. O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, Strony J, Tcheng JE. Platelet glycoprotein IIb/IIIa blockade with eptifibatide in coronary stent intervention. The ESPRIT trial: A randomized control trial. J Am Med Assoc 2001;285:2468-2473. (Pubitemid 32433840)
15. Sow MA, Molla A, Lamaty F, Lazaro R. Synthesis of RGD amphiphilic cyclic peptide as fibrinogen or fibronectin antagonist. Lett Pept Sci 1997;4:455-461. (Pubitemid 127505487)
16. Lestini BJ, Sagnella SM, Xu Z, Shive MS, Richter NJ, Jayaseharan J, Case AJ, Kottke-Marchant K, Anderson JM, Marchant RE. Surface modification of liposomes for selective targeting in cardiovascular drug delivery. J Control Release 2002;78:235-247. (Pubitemid 34081868)
17. Sen Gupta A, Huang G, Lestini BJ, Sagnella S, Kottke-Marchant K, Marchant RE. RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system. Thromb Haemost 2005;93:106-114. (Pubitemid 40124263)
18. Huang G, Zhou Z, Srinivasan R, Penn MS, Kotke-Marchant K, Marchant RE, Sen Gupta A. Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets. Biomaterials 2008;29:1676-1685.
19. Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 1990;35:161-214. (Pubitemid 20126875)
20. D'Souza SE, Haas TA, Piotrowicz RS, Byers-Ward V, McGrath DE, Soule HR, Cierniewski C, Plow EF, Smith JW. Ligand and cation binding are dual functions of a discrete segment of the integrin b3 subunit: Cation displacement is involved in ligand binding. Cell 1994;79:659-667. (Pubitemid 24363809)
21. Chandrasekar B, Tanguay J-F. Platelets and Restenosis. J Am Coll Cardiol 2000;35:555-562.
22. Le Breton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 1996;28:1643-1651. (Pubitemid 26426215)
23. Tsuruta W, Yamamoto T, Suzuki K, Yoshida F, Matsumura A. Simple new method for making a rat carotid artery post-angioplasty stenosis model. Neurol Med Chir 2007;47:525-529. (Pubitemid 350176068)
24. Sato N, Kiyokawa N, Takada K, Itagaki M, Saito M, Sekino T, Suzuki T, Taguschi T, Mimori K, Lanza F, Fujimoto J. Characterization of monoclonal antibodies against mouse and rat platelet glycoprotein V (CD42d). Hybridoma 2000;19:455-461. (Pubitemid 32015236)
25. Amiji M, editor. Nanotechnology for cancer therapy. Boca Raton, FL: CRC Press; 2007.
26. Nishiya T, Sloan S. Interaction of RGD liposomes with platelets. Biochem Biophys Res Commun 1996;224:242-245.